ALX Oncology Holdings Inc. (ALXO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Company: ALX Oncology Holdings Inc.
Reporting Period: Quarter and six months ended June 30, 2024.
Business Overview: ALX Oncology is a clinical-stage immuno-oncology company focused on developing therapies that block the CD47 checkpoint pathway. Its lead product candidate, evorpacept, is a next-generation CD47 blocker currently in multiple Phase 1 and Phase 2 clinical trials for various solid tumors and hematological malignancies. The company has no approved products and has not generated any product revenue to date.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(39,399) | $(34,159) | $(74,980) | $(64,343) |
| Net Loss Per Share (Basic/Diluted) | $(0.76) | $(0.84) | $(1.47) | $(1.57) |
| Operating Expenses | $41,525 | $36,777 | $79,287 | $68,980 |
| Research & Development (R&D) | $34,653 | $29,482 | $66,370 | $54,245 |
| General & Administrative (G&A) | $6,872 | $7,295 | $12,917 | $14,735 |
| Cash, Cash Equivalents & Investments | $186.2 million (as of June 30, 2024) | |||
| Term Loan (Non-current) | $9.8 million (outstanding principal $10.0 million) | |||
| Accumulated Deficit | $(561.3) million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 15% in Q2 2024 compared to Q2 2023, and by 17% for the six-month period. This was primarily driven by higher operating expenses.
- R&D Expenses: R&D expenses increased by 18% in Q2 and 22% for the six months ended June 30, 2024. Key drivers included:
- Increased preclinical costs for new targets.
- Higher personnel costs due to headcount growth.
- Increased stock-based compensation (partially due to reclassification of former CEO's compensation from G&A to R&D).
- A $1.0 million milestone payment to ScalmiBio stockholders in the first half of 2024.
- G&A Expenses: G&A expenses decreased by 6% in Q2 and 12% for the six months ended June 30, 2024, primarily due to a decrease in stock-based compensation expense (also influenced by the reclassification mentioned above).
- Liquidity: Cash and investments decreased from $215.8 million at year-end 2023 to $186.2 million at June 30, 2024, reflecting operating cash burn offset by investment maturities and ATM proceeds.
Guidance, Outlook, and Management Commentary
- Clinical Progress (Evorpacept):
- ASPEN-06 (Gastric/GEJ Cancer): Topline data announced in July 2024 showed a confirmed Overall Response Rate (ORR) of 40.3% for the evorpacept combination arm vs. 26.6% for control. In patients with fresh HER2-positive biopsies, ORR was 54.8% vs. 23.1%. Median Duration of Response was 15.7 months vs. 7.6 months.
- ASPEN-07 (Urothelial Cancer): Interim Phase 1 data presented at ASCO 2024 showed an unconfirmed ORR of 61% (n=26) for evorpacept plus enfortumab vedotin.
- Other Trials: Ongoing trials in Head and Neck Squamous Cell Carcinoma (HNSCC) and collaborations with Jazz, Sanofi, and Quantum Leap.
- Liquidity Outlook: Management believes existing cash, cash equivalents, investments, and funds available from the term loan will be sufficient to fund operations into the first quarter of 2026. The company expects to continue incurring significant losses as it advances clinical trials.
- Financing Activities: The company raised approximately $29.2 million in net proceeds through its At-The-Market (ATM) offering program during the six months ended June 30, 2024. The company decided not to draw down on the $40.0 million available under its term loan facility by the June 30, 2024 deadline; this amount was added to milestone-based tranches.
- Risks: Significant risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital, reliance on third-party manufacturers, and potential intellectual property disputes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $186.2 million cash position to fund operations through Q1 2026, considering potential acceleration of clinical trial costs.
- Clinical Data Validation: Review the full clinical study reports for ASPEN-06 and ASPEN-07 to confirm the durability and statistical significance of the reported response rates.
- Debt Covenants: Monitor compliance with the Oxford Finance/SVB term loan covenants, particularly regarding milestone achievements for future tranches.
- Intellectual Property: Assess the status of ongoing European patent oppositions (EP 2 429 574 and EP 2 995 315) regarding SIRPα technology which could impact market exclusivity.
- Manufacturing: Confirm the reliability and scalability of third-party contract manufacturing organizations (CMOs) for clinical and potential commercial supply.